IDM Pharma, Inc. announced updated results from the phase II study of its investigational agent IDM-2101 which showed the vaccine was well tolerated, induced broadly specific cytotoxic T lymphocyte (CTL) responses, and showed a positive survival trend in patients with non-small cell lung cancer (NSCLC) who were vaccinated with IDM-2101, compared to a parallel external control group of non-vaccinated patients.
"We are encouraged by the positive trend in overall survival we are seeing in patients who were treated with IDM-2101," said Minal Barve, M.D., practice director, Mary Crowley Cancer Research Centre. "We believe that the survival trend, as well as the tolerability and robust immunological response data, warrant further examination to confirm the treatment benefits of IDM-2101 for patients with non-small cell lung cancer."
The phase II open label, non-randomised trial with one year follow-up for survival was designed to assess overall survival and vaccine immunogenicity in HLA-A2 positive patients with stage IIIb, IV or recurrent non-small cell lung cancer. Patients were required to have tumour volume less than 125 cm squared with no limits on prior chemotherapy. Sixty-eight patients were enrolled in the trial (sixty-three treated with one or more doses) with the last patient enrolled in March 2006.
Updated one-year survival in patients treated with IDM-2101 was 60 per cent, compared to 49 per cent in a group of seventy-two patients who were HLA-A2 negative but otherwise comparable (external comparator group). Median survival for patients treated with IDM-2101 was 17.3 months compared to 12.0 months for patients in the comparator group. Ninety-one percent of patients treated with IDM-2101, who were tested for immune response, had a measurable response to at least one of the epitopes included in the vaccine with 64 percent responding to at least three of the epitopes. Toxicities attributable to the vaccine were mild and consisted primarily of injection site reactions.
"We are very encouraged by the continued positive survival trend and safety results of IDM-2101 in this study and are eager to continue development of this novel treatment," said Timothy P. Walbert, president and chief executive officer, IDM Pharma, Inc. "We will move forward with our plan to use the final results from this trial, which we expect next year, as a basis in determining an appropriate clinical pathway for IDM-2101."
IDM-2101 includes nine CTL epitopes from four tumour associated antigens (TAA) including two proprietary native epitopes and seven modified, or analogue, epitopes and one universal epitope a source of T-cell help. Tolerance to TAA, which is a failure of the immune system to recognize the cancer as diseased tissue, is broken by using these analogue epitopes which enhance the potency of the T cell response. The phase II IDM-2101 study has been ongoing since late 2004 and the last patient is expected to be treated in May 2008.
Lung cancer continues to be a major health problem with a very high mortality rate and represents the leading cause of cancer death in the United States. According to the American Cancer Society, approximately 213,000 new lung cancer cases will be diagnosed in the United States in 2007, and an estimated 160,000 patients will die from lung cancer. The American Cancer Society also estimates that non-small cell lung cancer represents 87 per cent of all lung cancers.
In the European Union, non-small cell lung cancer represents 75 per cent of all lung cancer. In addition, approximately 130,000 new cases will be diagnosed in 2007 in the top five markets (France, Germany, Italy, UK & Spain).
IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumour recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.